MIV, SagaX Sign Letter of Intent for Embolic-Protection Technology

MIV Therapeutics and SagaX Medical Technologies announced that they have entered into a letter of intent regarding SagaX's next generation embolic-protection technology for stroke patients. The parties hope to negotiate and execute definitive agreements regarding the transaction within the next few weeks.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=215230)